India's dual pricing pressures

Share this article:

India is struggling to keep its export drug business an enriching one. The Economic Times reports that international customers are aware of what the companies are charging in-country and now want similar prices for themselves. The Economic Times says companies are concerned that price parity would threaten their businesses, since India's price controls have driven prices down 60% for what the government considers essential medicines.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.